Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

• Status: Recruiting
• Trial end date: 2022-12-01

Summary

This is a prospective, multi-centre, open label, non-randomized phase II study evaluating the efficacy and safety of nivolumab plus platinum-based chemotherapy in patients with advanced G3 NENs of the GEP tract or of UK origin.

• Phase: Phase 2

Details

• Lead Sponsor: Grupo Espanol de Tumores Neuroendocrinos
• Treatments: Carboplatin; Etoposide; Etoposide phosphate; Nivolumab